The consortium’s objective, which has obtained €2.5 million from the Agencia Estatal de Investigación, is to advance to the clinical phase of the antifibrinolytic agent CM-352 A public-private consortium formed by the biotechnology company Hemostatics, based in the Parc Científic de Barcelona (PCB), the Clínica Universidad de Navarra (CUN), and the Institut Català d’Investigació Química […]